ProCE Banner Activity

New and Novel Advances in AML Therapeutics

Slideset

Download these expert-selected slides on novel investigational treatments and MRD testing in AML

Released: June 17, 2021

Expiration: June 16, 2022

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Astellas Pharma US

Pfizer, Inc.

Servier Pharmaceuticals

Faculty Disclosure

Primary Author

Eunice S. Wang, MD

Chief, Leukemia Service
Professor of Oncology
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Astellas, Blueprint, Daiichi Sankyo, Dark Blue, Dava Oncology, GlaxoSmithKline, Kite, Kura, Novartis, Qiagen, Rigel, Ryvu, Schrodinger, Servier, Stemline, Syndax, Pfizer, Takeda; data and safety monitoring: AbbVie.